CNTB - Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd Logo

CNTB - Connect Biopharma Holdings Ltd

https://www.connectbiopharm.com
Recent News
Powered by Alpha Vantage
Bullish
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology ( EAACI ) 2025 Annual Congress
GlobeNewswire • 3 months, 1 week ago • score: 0.29
SAN DIEGO, June 03, 2025 ( GLOBE NEWSWIRE ) -- Connect Biopharma Holdings Limited ( Nasdaq: CNTB ) ( "Connect Biopharma" or the "Company" ) , a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease ( COPD ) , ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators for the treatment of severe autoimmune diseases and inflammation. The company is headquartered in Taicang, China.

52W High
$2.86
52W Low
$0.51
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
-0.08
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
0.77
EV/EBITDA (<8 favorable)
0.19
EV/Revenue (<3 favorable)
13.54
P/S (TTM) (<3 favorable)
49.62
P/B (<3 favorable)
1.37
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
40.54%
Institutions (25–75% balanced)
44.24%
Shares Outstanding
55,722,000
Float
14,343,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
1,965,000
Gross Profit (TTM)
1,965,000
EPS (TTM)
-0.81
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-279.67%
ROE (TTM) (>15% strong)
-0.49%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—